A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 510 participants.
Also called NCT06559722
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 510 participants
- Sponsor
- Tonghua Dongbao Pharmaceutical Co.,Ltd
- Registry
-
NCT06559722
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT06559722. Randomized; no masking; primary purpose treatment. Start 2024-08 (anticipated); primary completion 2025-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Insulin Degludec/liraglutide Injection
- Intervention (Drug)
- XULTOPHY®
- Lead sponsor
- Tonghua Dongbao Pharmaceutical Co.,Ltd
Record details
- Record id
cardio:ct-nct06559722- Content hash
1dbbf00b6e571c881c2438c0869d146e7f1b6a71dc873c16a6d6e7ac229b3244